Author

Tamás Resál

COMPARATIVE OUTCOMES AND SAFETY OF BUDESONIDE-MMX VERSUS PREDNISOLONE FOR ULCERATIVE COLITIS AND POSSIBLE GENETICAL PREDICTORS OF SIDE-EFFECTS
COMPARATIVE OUTCOMES AND SAFETY OF BUDESONIDE-MMX VERSUS PREDNISOLONE FOR ULCERATIVE COLITIS AND POSSIBLE GENETICAL PREDICTORS OF SIDE-EFFECTS

COMPARATIVE OUTCOMES AND SAFETY OF BUDESONIDE-MMX VERSUS PREDNISOLONE FOR ULCERATIVE COLITIS AND POSSIBLE GENETICAL PREDICTORS OF SIDE-EFFECTS
COMPARATIVE OUTCOMES AND SAFETY OF BUDESONIDE-MMX VERSUS PREDNISOLONE FOR ULCERATIVE COLITIS AND POSSIBLE GENETICAL PREDICTORS OF SIDE-EFFECTS

Tamás Resál  et al.

THE PREDICTIVE VALUE OF IRON DEFICIENCY ANAEMIA AND THE SEVERITY OF ANAEMIA ON THE ONE-YEAR DISEASE COURSE OF INFLAMMATORY BOWEL DISEASE
THE PREDICTIVE VALUE OF IRON DEFICIENCY ANAEMIA AND THE SEVERITY OF ANAEMIA ON THE ONE-YEAR DISEASE COURSE OF INFLAMMATORY BOWEL DISEASE

Tamás Resál  et al.

REAL-LIFE EFFECTIVENESS OF TOFACITINIB IN TWO INDICATIONS IN ULCERATIVE COLITIS: A RETROSPECTIVE WORLDWIDE, MULTICENTER, COLLABORATIVE STUDY
REAL-LIFE EFFECTIVENESS OF TOFACITINIB IN TWO INDICATIONS IN ULCERATIVE COLITIS: A RETROSPECTIVE WORLDWIDE, MULTICENTER, COLLABORATIVE STUDY

Tamás Resál  et al.

EFFICACY OF INTRAVENOUS FERRIC CARBOXYMALTOSE TREATMENT IS INDEPENDENT FROM DISEASE ACTIVITY AND DOES NOT REQUIRE THERAPY OPTIMISATION IN CASE OF SILENT IBD WITH IDA – A PROSPECTIVE STUDY
EFFICACY OF INTRAVENOUS FERRIC CARBOXYMALTOSE TREATMENT IS INDEPENDENT FROM DISEASE ACTIVITY AND DOES NOT REQUIRE THERAPY OPTIMISATION IN CASE OF SILENT IBD WITH IDA – A PROSPECTIVE STUDY

Tamás Resál  et al.

LDN-051 A NOVEL FECAL BIOMARKER FOR MONITORING DISEASE ACTIVITY AND THERAPEUTIC RESPONSE IN INFLAMMATORY BOWEL DISEASES – RESULTS OF A PHASE 2 CLINICAL TRIAL
LDN-051 A NOVEL FECAL BIOMARKER FOR MONITORING DISEASE ACTIVITY AND THERAPEUTIC RESPONSE IN INFLAMMATORY BOWEL DISEASES – RESULTS OF A PHASE 2 CLINICAL TRIAL

Tamás Resál  et al.

SHOTGUN ANALYSIS OF GUT MICROBIOTA WITH BODY COMPOSITION AND LIPID CHARACTERISTICS IN CROHN'S DISEASE
SHOTGUN ANALYSIS OF GUT MICROBIOTA WITH BODY COMPOSITION AND LIPID CHARACTERISTICS IN CROHN'S DISEASE

Tamás Resál  et al.

USTEKINUMAB IS ASSOCIATED WITH SUPERIOR TREATMENT PERSISTENCE BUT NOT WITH HIGHER REMISSION RATES COMPARED TO VEDOLIZUMAB IN REFRACTORY CROHN’S DISEASE PATIENTS: RESULTS FROM A MULTICENTRE COHORT STUDY
USTEKINUMAB IS ASSOCIATED WITH SUPERIOR TREATMENT PERSISTENCE BUT NOT WITH HIGHER REMISSION RATES COMPARED TO VEDOLIZUMAB IN REFRACTORY CROHN’S DISEASE PATIENTS: RESULTS FROM A MULTICENTRE COHORT STUDY

Tamás Resál  et al.

USTEKINUMAB IS SUPERIOR IN TREATMENT PERSISTENCE AND COLECTOMY-FREE SURVIVAL AMONG SEQUENTIAL BIOLOGICAL THERAPIES IN MODERATE-TO-SEVERE ULCERATIVE COLITIS REFRACTORY TO ANTI-TNF – PRELIMINARY DATA OF A RETROSPECTIVE, MULTICENTRE STUDY
USTEKINUMAB IS SUPERIOR IN TREATMENT PERSISTENCE AND COLECTOMY-FREE SURVIVAL AMONG SEQUENTIAL BIOLOGICAL THERAPIES IN MODERATE-TO-SEVERE ULCERATIVE COLITIS REFRACTORY TO ANTI-TNF – PRELIMINARY DATA OF A RETROSPECTIVE, MULTICENTRE STUDY

Tamás Resál  et al.

ACCURACY OF PANMAYO ENDOSCOPIC SCORE IN PREDICTING LONG-TERM DISEASE OUTCOMES IN ULCERATIVE COLITIS– A PROMISING SCORING SYSTEM
ACCURACY OF PANMAYO ENDOSCOPIC SCORE IN PREDICTING LONG-TERM DISEASE OUTCOMES IN ULCERATIVE COLITIS– A PROMISING SCORING SYSTEM

Tamás Resál  et al.

CHARACTERIZATION OF THE CYTOKINE EXPRESSION IN HUMAN COLON ORGANOIDS FROM INFLAMMATORY BOWEL DISEASE PATIENTS
CHARACTERIZATION OF THE CYTOKINE EXPRESSION IN HUMAN COLON ORGANOIDS FROM INFLAMMATORY BOWEL DISEASE PATIENTS

Tamás Resál  et al.

INCREASED EXPRESSION OF SERPIN E1, A POTENTIAL NEW ACTIVITY MARKER, REFLECTS ENDOSCOPIC ACTIVITY AND THERAPEUTIC NON-RESPONSE IN INFLAMMATORY BOWEL DISEASE
INCREASED EXPRESSION OF SERPIN E1, A POTENTIAL NEW ACTIVITY MARKER, REFLECTS ENDOSCOPIC ACTIVITY AND THERAPEUTIC NON-RESPONSE IN INFLAMMATORY BOWEL DISEASE

Tamás Resál  et al.

NON-MEDICAL, MANDATORY SWITCH AMONG ADALIMUMAB BIOSIMILARS AND FROM THE ORIGINATOR ADALIMUMAB TO BIOSIMILARS IN INFLAMMATORY BOWEL DISEASE PATIENTS – A PROSPECTIVE, MULTICENTRE STUDY ON EFFICACY, DRUG SUSTAINABILITY AND SAFETY
NON-MEDICAL, MANDATORY SWITCH AMONG ADALIMUMAB BIOSIMILARS AND FROM THE ORIGINATOR ADALIMUMAB TO BIOSIMILARS IN INFLAMMATORY BOWEL DISEASE PATIENTS – A PROSPECTIVE, MULTICENTRE STUDY ON EFFICACY, DRUG SUSTAINABILITY AND SAFETY

Tamás Resál  et al.

HEAVY PSEUDOPOLYP BURDEN IN INFLAMMATORY BOWEL DISEASE PREDICTS MORE SEVERE DISEASE: A MULTICENTRE COHORT STUDY
HEAVY PSEUDOPOLYP BURDEN IN INFLAMMATORY BOWEL DISEASE PREDICTS MORE SEVERE DISEASE: A MULTICENTRE COHORT STUDY

Tamás Resál  et al.

POTENTIAL BIOMARKER PAI-1 PROMOTES THE DISEASE ACTIVITY AND THERAPEUTIC RESPONSE IN BIOLOGICAL SAMPLES OF INFLAMMATORY BOWEL DISEASES
POTENTIAL BIOMARKER PAI-1 PROMOTES THE DISEASE ACTIVITY AND THERAPEUTIC RESPONSE IN BIOLOGICAL SAMPLES OF INFLAMMATORY BOWEL DISEASES

Tamás Resál  et al.

PROACTIVE MEASUREMENT OF FAECAL INFLIXIMAB IN ULCERATIVE COLITIS POTENTIALLY INCREASES THE ACCURACY OF DISEASE MONITORING AND HELPS TO ACHIEVE THERAPEUTIC TARGET
PROACTIVE MEASUREMENT OF FAECAL INFLIXIMAB IN ULCERATIVE COLITIS POTENTIALLY INCREASES THE ACCURACY OF DISEASE MONITORING AND HELPS TO ACHIEVE THERAPEUTIC TARGET

Tamás Resál  et al.

INCIDENCE AND PREDICTORS OF POST-COLONOSCOPY COLORECTAL CANCER – POPULATION-BASED RETROSPECTIVE STUDY
INCIDENCE AND PREDICTORS OF POST-COLONOSCOPY COLORECTAL CANCER – POPULATION-BASED RETROSPECTIVE STUDY

Tamás Resál  et al.

THE RISK OF MALIGNANCY OF DIAGNOSTIC CATEGORIES DEFINED BY PAPANICOLAOU SOCIETY OF CYTOPATHOLOGY SYSTEM IN EUS-FNA SAMPLING OF SOLID PANCREATIC LESIONS
THE RISK OF MALIGNANCY OF DIAGNOSTIC CATEGORIES DEFINED BY PAPANICOLAOU SOCIETY OF CYTOPATHOLOGY SYSTEM IN EUS-FNA SAMPLING OF SOLID PANCREATIC LESIONS

Tamás Resál  et al.

ADHERENCE TO THE HUNGARIAN POPULATION-BASED COLORECTAL SCREENING PROGRAM AND POTENTIAL INFLUENCING DEMOGRAPHIC FACTORS
ADHERENCE TO THE HUNGARIAN POPULATION-BASED COLORECTAL SCREENING PROGRAM AND POTENTIAL INFLUENCING DEMOGRAPHIC FACTORS

Tamás Resál  et al.

Item 1 - 19 / 19
1